Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer

Abstract

Capecitabine and oxaliplatin are as effective as fluorouracil and cisplatin, respectively, in patients with previously untreated esophagogastric cancer. (Current Controlled Trials number, ISRCTN51678883 [controlled-trials.com].).

Keywords

MedicineCapecitabineOxaliplatinInternal medicineEsophagogastric junctionOncologyCancerGastroenterologyColorectal cancerAdenocarcinoma

Affiliated Institutions

Related Publications

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

Salah‐Eddin Al‐Batran , Nils Homann , Claudia Pauligk +54 more

Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma. This study reports on the safety and efficacy of the docetaxel-ba...

2019 The Lancet 2355 citations

Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie

Salah‐Eddin Al‐Batran , J. T. Hartmann , Stephan Probst +17 more

Purpose This study was designed to compare fluorouracil, leucovorin, and oxaliplatin with fluorouracil, leucovorin, and cisplatin in patients with advanced gastric cancer. Patie...

2008 Journal of Clinical Oncology 775 citations

Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer

David Cunningham , William Allum , Sally Stenning +12 more

In patients with operable gastric or lower esophageal adenocarcinomas, a perioperative regimen of ECF decreased tumor size and stage and significantly improved progression-free ...

2006 New England Journal of Medicine 6200 citations

Prospective Randomized Trial Comparing Mitomycin, Cisplatin, and Protracted Venous-Infusion Fluorouracil (PVI 5-FU) With Epirubicin, Cisplatin, and PVI 5-FU in Advanced Esophagogastric Cancer

Paul J. Ross , M. Nicolson , David Cunningham +9 more

PURPOSE: We report the results of a prospectively randomized study that compared the combination of epirubicin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU)...

2002 Journal of Clinical Oncology 481 citations

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Yelena Y. Janjigian , Kohei Shitara , Markus Moehler +26 more

First-line chemotherapy for advanced or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma has a median ov...

2021 The Lancet 2580 citations

Publication Info

Year: 2008
Type: article
Volume: 358
Issue: 1
Pages: 36-46
Citations: 2285
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2285

OpenAlex

Cite This

APA Style

                            
                                
                                    David Cunningham, 
                                
                                    Naureen Starling, 
                                
                                    Sheela Rao
                                
                                et al.
                            
                            (2008). 
                            Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer. 
                            New England Journal of Medicine
                            , 358
                            (1)
                            , 36-46.
                            https://doi.org/10.1056/nejmoa073149
                        

Identifiers

DOI: 10.1056/nejmoa073149